ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.070,57
0,43%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07699
0,11%
Bitcoin
65.211,03
1,89%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) News

HCM Hutchmed (china) Limited

310,00
0,00 (0,00%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Hutchmed (china) Limited HCM London Ordinary Share
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 310,00 17:35:23
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
311,00 303,00 314,00 310,00 310,00
more quote information »
Industriesektor
PHARMACEUTICALS & BIOTECHNOLOGY

Aktuelle News

Datum Zeit Quelle Überschrift
26.4.202417:09ALNCNewsHutchmed notes CHMP's positive opinion for fruiquintinib..
26.4.202414:30UK RNSHutchmed (China) Limited Positive CHMP Opinion for..
22.4.202410:30UK RNSHutchmed (China) Limited Vesting of Awards Under the LTIP
08.4.202410:30UK RNSHutchmed (China) Limited 2023 Annual Report and Notice of..
05.4.202410:30UK RNSHutchmed (China) Limited Data to be Presented at AACR..
02.4.202411:32ALNCNewsHutchmed endometrial cancer treatment application accepted..
02.4.202408:00UK RNSHutchmed (China) Limited HUTCHMED and Innovent Announce NDA..
28.3.202412:08ALNCNewsHutchmed lung cancer treatment accepted for review in China
28.3.202408:00UK RNSHutchmed (China) Limited Savolitinib sNDA Accepted in China
22.3.202411:09ALNCNewsHutchmed begins registration stage for sovleplenib phase 2/3..
22.3.202408:16ALNCNews*CORRECT: Hutchmed China initiates registration for phase 3..
22.3.202408:00UK RNSHutchmed (China) Limited Initiation of Registration Stage of..
14.3.202410:00UK RNSHutchmed (China) Limited LTIP and Share Option Scheme
05.3.202409:30UK RNSHutchmed (China) Limited Vesting of awards under the LTIP
28.2.202418:31ALNCNewsEARNINGS: Hutchmed revenue surges, Craven House's loss..
28.2.202413:45UK RNSHutchmed (China) Limited Publication of Form 20-F
28.2.202412:30UK RNSHutchmed (China) Limited 2023 Full Year Results and Business..
07.2.202410:50ALNCNewsHutchmed hails fruquintinib trial results for gastric cancer..
07.2.202408:00UK RNSHutchmed (China) Limited Presentation of Phase III Data on..
02.2.202410:52ALNCNewsHutchmed says Inmagene exercises option to licence drug..
02.2.202409:37UK RNSHutchmed (China) Limited Inmagene Exercises Option for Two..
01.2.202409:30UK RNSHutchmed (China) Limited HUTCHMED to Announce 2023 Final..
30.1.202410:20ALNCNewsHutchmed celebrates cancer drug approval in hometown of Hong..
30.1.202408:12UK RNSHutchmed (China) Limited HUTCHMED Receives Marketing..
11.1.202411:17ALNCNewsTOP NEWS: Hutchmed Sovleplenib accepted for review by China..
11.1.202408:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
29.12.202309:30UKREGHutchmed (China) Limited Total Voting Rights
29.12.202309:30UKREGHutchmed (China) Limited Blocklisting Six Monthly Return
21.12.202312:36ALNCNewsIN BRIEF: Hutchmed China renews deals with "substantial"..
21.12.202311:00UKREGHutchmed (China) Limited Overseas Regulatory Announcement
13.12.202314:56ALNCNewsHutchmed completes enrolment for fruquintinib trial
13.12.202308:00RNSNONHutchmed (China) Limited Completed Enrollment of Phase..
07.12.202311:04UKREGHutchmed (China) Limited Overseas Regulatory Announcement
01.12.202308:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
30.11.202309:30UKREGHutchmed (China) Limited Total Voting Rights
09.11.202313:16ALNCNewsHutchmed hails Takeda's fruquintinib approval from US for..
09.11.202308:00UKREGHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM)..
24.10.202310:30UKREGHutchmed (China) Limited Vesting of awards under the LTIP
16.10.202310:30RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
29.9.202311:12ALNCNewsHutchmed notes Takeda submits fruquintinib drug application..
29.9.202310:30UKREGHutchmed (China) Limited Total Voting Rights
29.9.202310:30RNSNONHutchmed (China) Limited NDA Submission for Fruquintinib in..
14.9.202310:30UKREGHutchmed (China) Limited Director's Share Dealing
12.9.202311:26ALNCNewsIN BRIEF: Hutchmed China finalises patient enrolment for..
12.9.202310:30RNSNONHutchmed (China) Limited Phase IIIb Savolitinib Results at..
12.9.202308:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
31.8.202310:30UKREGHutchmed (China) Limited Total Voting Rights
29.8.202310:30ALNCNewsIN BRIEF: China grants Hutchmed's savolitinib breakthrough..
29.8.202308:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
21.8.202309:46ALNCNewsHutchmed China hails trial on sovleplenib meeting primary..

Kürzlich von Ihnen besucht

LSE
HCM
Hutchmed (china)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten